CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...